Yes but it’s not open access. In England, tirzepatide (Mounjaro) is being introduced through the NHS using phased access, meaning only certain priority cohorts get access first, while services build capacity, training, governance, and wraparound support.

If you want the main product overview first, use: Mounjaro weight loss injection pen.

Table of Contents

Quick answer: what “phased access” means (in plain English)

You can get Mounjaro on the NHS in England if:

you meet the clinical criteria, and
your local NHS system (ICB/services) has an active delivery pathway (specialist service or primary-care model), and
you take part in the mandatory wraparound care that must accompany prescribing.

Because of demand and capacity, NHS England and NICE agreed a funding variation and a cohorting approach to prioritise who gets treated first.

Timeline: what changed and when

Here are the dates that matter most for NHS access in England:

1) 23 March 2025 – specialist services only (patient-facing NHS England page)

NHS England’s patient guidance states that from 23 March 2025, you may be prescribed tirzepatide (Mounjaro) for weight management only if prescribed by a specialist weight management service (where multidisciplinary support like dietitians and psychologists exists).

2) 24 March 2025 – funding mandate starts for specialist services (full eligible NICE cohort)

NHS England’s interim commissioning guidance says that from 24 March 2025, ICBs are required to fund access in specialist weight management services for people who meet NICE TA1026 eligibility, where a prescribing clinician approves treatment.

3) 23 June 2025 – primary care funding begins, but only for phased priority cohorts

The same NHS England interim commissioning guidance states ICBs are required to fund access in primary care from 23 June 2025, but only for prioritised patient cohorts, phased due to primary care capacity.

4) 2025–2028 – first 3 years treat ~220,000 people; full access can take up to 12 years

NHS England’s guidance explains the funding variation aims to treat around 220,000 people over the first 3 years, while total eligible access is expected within a maximum of 12 years, based on prioritisation by clinical need.

Who gets it first? (Cohorting criteria that decide NHS priority)

Even if you meet broad “NICE eligibility”, primary care access is cohort-based at the start.

NHS England’s interim commissioning guidance sets out the first cohorts like this:

Cohort table (initial 3-year phasing in primary care)

Funding year	Cohort	BMI band	Comorbidity requirement
Year 1 (2025/26)	I	BMI ≥ 40	≥ 4 qualifying comorbidities
Year 2 (2026/27)	II	BMI 35–39.9	≥ 4 qualifying comorbidities
Year 2/3 (2026 & 2027/28)	III	BMI ≥ 40	3 qualifying comorbidities

Important detail: NHS England also notes you should use a lower BMI threshold (usually −2.5 kg/m²) for certain ethnic backgrounds (South Asian, Chinese, other Asian, Middle Eastern, Black African, African-Caribbean).

Qualifying comorbidities: what counts (and how they’re defined)

NHS England’s interim guidance defines qualifying comorbidities for the early cohorts and gives clinical definitions used in assessment.

The “qualifying comorbidities” used for cohorting include:

Atherosclerotic cardiovascular disease (ASCVD) (e.g., ischaemic heart disease, cerebrovascular disease, peripheral vascular disease, heart failure)
Hypertension requiring blood-pressure-lowering therapy
Dyslipidaemia (treated with lipid-lowering therapy or specific lipid thresholds)
Obstructive sleep apnoea (OSA) confirmed by sleep study with treatment indicated (e.g., CPAP criteria)
Type 2 diabetes mellitus

This is why some people who “meet BMI rules” still don’t qualify for early NHS access: early access is based on BMI + number/complexity of comorbidities.

Where is it prescribed? (specialist services vs primary care models)

Specialist weight management services (SWMS)

This is the earliest and most consistent NHS pathway mentioned in NHS England patient guidance (specialists decide if it’s right for you, with multidisciplinary support).

Primary care (from 23 June 2025) – multiple delivery models

NHS England’s interim guidance describes four indicative models for primary-care delivery (ICBs can choose what fits locally), such as:

community/local delivery,
general practice delivery,
specialist service community outreach,
shared-care between specialist services and general practice.

That’s why you’ll see different experiences by region: some areas move faster with primary-care models; others rely mostly on specialist services first.

Wraparound care is mandatory (this is a hard rule)

If you’re trying to understand why the NHS keeps saying “support programme” this is the reason:

NHS England states that wraparound care is a required treatment component when tirzepatide is prescribed for weight management, aligned with NICE TA1026 and the MHRA licence.

It also explains nationally procured behavioural support is delivered over 9 consecutive months (digital/remote/face-to-face options).

Local NHS pages repeat the same practical rule:

if you don’t want wraparound care, you can’t be prescribed tirzepatide.

Why access can vary by area (the postcode problem)

Even with national rules, ICBs control local implementation (funding, service model, capacity). NHS England’s interim guidance explicitly mentions managing primary care capacity and allows local flexibility in models.

This local variability has been widely reported as a “postcode lottery” in the early rollout, with some areas prescribing earlier than others and some tightening criteria.

What this means for your page:
When someone asks “Can I get it on the NHS?”, the honest answer is:

Nationally: yes, phased
Locally: depends whether your ICB pathway is active and which cohort they’re implementing

What to do next (patient action plan)

Step 1 – Check if you’re likely in an early priority cohort

If you have:

BMI ≥ 40, and
3-4+ qualifying comorbidities (hypertension, dyslipidaemia, OSA, ASCVD, type 2 diabetes),
you are closer to the early cohorts.

Step 2 – Gather the information services will verify

Expect services to verify:

BMI measurement,
diagnosed comorbidities (and treatments),
current meds and medical history.

Step 3 – Ask your GP about your local route (SWMS referral vs PCN service)

Because access can be through specialist services or primary-care models (depending on your area), your GP is usually the starting point to identify:

whether your ICB uses SWMS prescribing,
whether your area has started primary-care prescribing for priority cohorts,
what referral pathway exists.

Step 4 – Be ready to join wraparound care

If you qualify and your area is prescribing, you should expect a requirement to participate in wraparound behavioural support (often described as essential/mandatory).

FAQs

When did the NHS start prescribing Mounjaro for weight loss?

NHS England patient guidance says that from 23 March 2025, prescribing for weight management was via specialist weight management services.
NHS England’s interim commissioning guidance sets the funding mandate in specialist services from 24 March 2025, and in primary care from 23 June 2025 (phased cohorts).

What are the first NHS cohorts?

In primary care phasing, NHS England lists early cohorts based on BMI and number of qualifying comorbidities (e.g., BMI ≥40 with ≥4 comorbidities first).

Do I have to do a support programme?

Yes. NHS England states wraparound care is a required part of prescribing tirzepatide for weight management, and local NHS pages note you can’t be prescribed it if you won’t participate.

Why can my friend get it in another city but I can’t?

Because ICBs implement pathways differently (capacity, models, timing), creating access variation that has been reported nationally.